Compare JAGX & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | BBLG |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.6M |
| IPO Year | 2014 | N/A |
| Metric | JAGX | BBLG |
|---|---|---|
| Price | $0.49 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 400.4K | 23.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,689,000.00 | N/A |
| Revenue This Year | $22.41 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.75 | N/A |
| 52 Week Low | $0.20 | $0.57 |
| 52 Week High | $15.48 | $5.98 |
| Indicator | JAGX | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 41.11 |
| Support Level | N/A | $1.11 |
| Resistance Level | $0.69 | $1.88 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 1.58 | 42.86 |
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.